Changes in pharmaceutical treatment of diabetes and family financial burdens

Medical Care Research and Review

Volumn 69, Issue 4, 2012, Pages 474-491

  Sarpong, Eric M ^a   Bernard, Didem M ^a   Miller, G Edward ^a  

^a AGENCY FOR HEALTHCARE RESEARCH AND QUALITY   (United States)

Author keywords

comorbidities; diabetes; financial burden; nonelderly adults; out of pocket drug expenditures

Indexed keywords

ANTIDIABETIC AGENT; ORAL ANTIDIABETIC AGENT;

ADOPTION; ADULT; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DISORDERS OF LIPID METABOLISM; DRUG COST; FEMALE; GROUPS BY AGE; HEALTH INSURANCE; HUMAN; HYPERTENSION; INCOME; MALE; MARRIAGE; PREVALENCE; REVIEW;

ADOLESCENT; ADULT; AGE FACTORS; COST OF ILLNESS; DIABETES MELLITUS; DRUG COSTS; FEMALE; FINANCING, PERSONAL; HEALTH CARE COSTS; HUMANS; HYPOGLYCEMIC AGENTS; INCOME; INSURANCE COVERAGE; INSURANCE, HEALTH; MALE; MIDDLE AGED; POVERTY; SEX FACTORS; UNITED STATES; YOUNG ADULT;

EID: 84864208720     PISSN: 10775587     EISSN: 15526801     Source Type: Journal    
DOI: 10.1177/1077558712442570     Document Type: Review

References (29)

1. Alexander G. C., Sehgal N. L., Moloney R. M., Stafford R. S.. National change in treatment of type 2 diabetes mellitus, 1994-2007. Archives of Internal Medicine. 2008 ; 168: 2088-2094
2. Standards of medical care in diabetes-2009. Diabetes Care. 2009 ; 32 (1). S13 - S61
3. Banthin J. S., Bernard D. M.. Changes in financial burdens for health care: National estimates for the population younger than 65 years, 1996 to 2003. Journal of the American Medical Association. 2006 ; 296: 2712-2719 (Pubitemid 44917548)
4. Banthin J. S., Cunningham P. J., Bernard D. M.. Financial burden of health care, 2001-2004. Health Affairs. 2008 ; 27: 188-195 (Pubitemid 351198604)
5. Bernard D. M., Banthin J. S., Encinosa W. E.. Health care expenditure burdens among adults with diabetes, 2001. Medical Care. 2006 ; 44: 210-215 (Pubitemid 43755447)
6. Centers for Disease Control and Prevention. (2008). National diabetes fact sheet: General information and national estimates on diabetes in the United States, 2007. Atlanta, GA: Author. Retrieved from http://www.cdc.gov/diabetes/ pubs/pdf/ndfs-2007.pdf
7. CohenJ. W. (1997). Design and methods of the medical expenditures panel survey household component (Methodology Report No. 1). Rockville, MD: Agency for Healthcare Policy and Research. Retrieved from http://meps.ahrq.gov/mepsweb/ data-files/publications/mr1/mr1.shtml
8. Cunningham P. J.. The growing financial burden of health care: National and state change, 2001-2006. Health Affairs. 2010 ; 29: 1037-1044
9. Dall T. M., Mann S. E., Zhang Y., Quick W. W., Seifert R. F., Martin J.,... Zhang S.. Distinguishing the economic costs associated with type 1 and type 2 diabetes. Population Health Management. 2009 ; 12: 103-110
10. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New England Journal of Medicine. 1993 ; 329: 977-986
11. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 1997 ; 20: 1183-1197
12. Galbraith A. A., Wong S. T., Kim S. E., Newacheck P. W.. Out-of-pocket financial burden for low-income families with children: Socioeconomic disparities and effects of insurance. Health Services Research. 2005 ; 40: 1722-1736 (Pubitemid 41814233)
13. Gellad W. F., Donohue J. M., Zhao X., Zhang Y., Banthin J. S.. The financial burden from prescription drugs has declined recently for the nonelderly, although it is still high for many. Health Affairs. 2012 ; 31: 408-416
14. Gibson T. B., Ozminkowski R. J., Goetzel R. Z.. The effects of prescription drug cost sharing: A review of the evidence. American Journal of Managed Care. 2005 ; 11: 730-740 (Pubitemid 41608213)
15. Heisler M., Langa K. M., Eby E. L., Fendrick A. M., Kabeto M. U., Piette J. D.. The health effects of restricting prescription medication use because of cost. Medical Care. 2004 ; 42: 626-634
16. Hill S. C., Miller G. E., Sing M.. Adults with diagnosed and untreated diabetes: Who are they? How can we reach them?. Journal of Healthcare for the Poor and Underserved. 2011 ; 22: 1221-1238
17. Johnson J. A., Pohar S. L., Majumdar S. R.. Health care use and costs in the decade after identification of type 1 and type 2 diabetes: A population-based study. Diabetes Care. 2006 ; 29: 2403-2408 (Pubitemid 44912243)
18. Kesselheim A. S., Fischer M. A., Avorn J.. Extensions of intellectual property rights and delayed adoption of generic drugs: Effects on Medicaid spending. Health Affairs. 2006 ; 25: 1637-1647 (Pubitemid 44871732)
19. Mann D. M., Woodward M., Ye F., Krousel-Wood M., Muntner P.. Change in drug use among U.S. adults with diabetes mellitus: Glycemic control at the expense of controlling cardiovascular risk factors. Archives of Internal Medicine. 2009 ; 169: 1718-1720
20. Nathan D. M., Buse J. B., Davidson M. B., Ferrannini E., Holman R. R., Sherwin R., Zinman B.. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009 ; 32: 193-203
21. Nichols G. A., Alexander C. M., Girman C. J., Kamal-Bahl S. J., Brown J. B.. Contemporary analysis of secondary failure of successful sulfonylurea therapy. Endocrine Practice. 2007 ; 13: 37-44
22. Parish S. L., Shattuck P. T., Rose R. A.. Financial burden of raising CSHCN: Association with state policy choices. Pediatrics. 2009 ; 124: S435 - S442
23. Piette J. D., Heisler M., Wagner T. H.. Cost-related medication underuse among chronically ill adults: The treatments people forgo, how often, and who is at risk. American Journal of Public Health. 2004a ; 94: 1782-1787 (Pubitemid 39331770)
24. Piette J. D., Heisler M., Wagner T. H.. Problems paying out-of-pocket medication costs among older adults with diabetes. Diabetes Care. 2004b ; 27: 384-391 (Pubitemid 38174062)
25. Rizzo J., Zeckhauser R.. Generic script share and the price of brand-name drugs: The role of consumer choice. International Journal of Health Care Finance and Economics. 2009 ; 9: 291-316
26. SarpongE. M.MillerG. E. (2010). Change in the pharmaceutical treatment of diabetes, 1997 to 2007 (Research Findings No. 30). Rockville, MD: Agency for Healthcare Research and Quality. Retrieved from http://meps.ahrq.gov/mepsweb/ data-files/publications/rf30/rf30.pdf
27. Thorpe K. E.. The rise in health care spending and what to do about it. Health Affairs. 2005 ; 24: 1436-1445
28. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998a ; 352: 837-853
29. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998b ; 352: 854-865